Literature DB >> 11525659

Asymmetric total synthesis of ent-(-)-roseophilin: assignment of absolute configuration.

D L Boger1, J Hong.   

Abstract

An asymmetric total synthesis of ent-(-)-roseophilin (1), the unnatural enantiomer of a novel naturally occurring antitumor antibiotic, is described. The approach enlists a room temperature heterocyclic azadiene inverse electron demand Diels-Alder reaction of dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate (7) with the optically active enol ether 6 bearing the C23 chiral center followed by a reductive ring contraction reaction for formation of an appropriately functionalized pyrrole ring in a key 1,2,4,5-tetrazine --> 1,2-diazine --> pyrrole reaction sequence. A Grubbs' ring closing metathesis reaction was utilized to close the unusual 13-membered macrocycle prior to a subsequent 5-exo-trig acyl radical-alkene cyclization that was used to introduce the fused cyclopentanone and complete the preparation of the tricylic ansa-bridged azafulvene core 32. Condensation of 32 with 33 under the modified conditions of Tius and Harrington followed by final deprotection provided (22S,23S)-1. Comparison of synthetic (22S,23S)-1 ([alpha](25)(D), CD) with natural 1 established that they were enantiomers and enabled the assignment of the absolute stereochemistry of the natural product as 22R,23R. Surprisingly, ent-(-)-1 was found to be 2-10-fold more potent than natural (+)-1 in cytotoxic assays, providing an unusually rewarding culmination to synthetic efforts that provided the unnatural enantiomer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525659     DOI: 10.1021/ja011271s

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  21 in total

1.  Total synthesis of dihydrolysergic acid and dihydrolysergol: development of a divergent synthetic strategy applicable to rapid assembly of D-ring analogs.

Authors:  Kiyoun Lee; Yam B Poudel; Christopher M Glinkerman; Dale L Boger
Journal:  Tetrahedron       Date:  2015-09-02       Impact factor: 2.457

2.  Chiral Brønsted base-promoted nitroalkane alkylation: enantioselective synthesis of sec-alkyl-3-substituted indoles.

Authors:  Mark C Dobish; Jeffrey N Johnston
Journal:  Org Lett       Date:  2010-11-19       Impact factor: 6.005

3.  Formal synthesis of (+/-)-roseophilin.

Authors:  Abdallah Y Bitar; Alison J Frontier
Journal:  Org Lett       Date:  2009-01-01       Impact factor: 6.005

4.  Functional analysis of an aspartate-based epoxidation catalyst with amide-to-alkene peptidomimetic catalyst analogues.

Authors:  Charles E Jakobsche; Gorka Peris; Scott J Miller
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Synthesis, Characterization, and Rapid Cycloadditions of 5-Nitro-1,2,3-triazine.

Authors:  Christopher M Glinkerman; Dale L Boger
Journal:  Org Lett       Date:  2018-04-16       Impact factor: 6.005

6.  Cycloadditions of 1,2,3-Triazines Bearing C5-Electron Donating Substituents: Robust Pyrimidine Synthesis.

Authors:  Christopher M Glinkerman; Dale L Boger
Journal:  Org Lett       Date:  2015-07-14       Impact factor: 6.005

7.  Inverse electron demand Diels-Alder reactions of 1,2,3-triazines: pronounced substituent effects on reactivity and cycloaddition scope.

Authors:  Erin D Anderson; Dale L Boger
Journal:  J Am Chem Soc       Date:  2011-07-19       Impact factor: 15.419

8.  Scope of the inverse electron demand Diels-Alder reactions of 1,2,3-triazine.

Authors:  Erin D Anderson; Dale L Boger
Journal:  Org Lett       Date:  2011-04-13       Impact factor: 6.005

9.  Modular access to complex prodiginines: total synthesis of (+)-roseophilin via its 2-azafulvene prototropisomer.

Authors:  James H Frederich; Patrick G Harran
Journal:  J Am Chem Soc       Date:  2013-03-01       Impact factor: 15.419

10.  Mirror-image carbohydrates: synthesis of the unnatural enantiomer of a blood group trisaccharide.

Authors:  Fabien P Boulineau; Alexander Wei
Journal:  J Org Chem       Date:  2004-05-14       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.